Lapatinib
CAS 231277-92-2
In Stock
Lapatinib
Cat. No. STUB-API-LAPATINIBCAS 231277-92-2In Stock
Technical Data
Cat. No.STUB-API-LAPATINIB
CAS231277-92-2
Mol. FormulaC29H26ClFN4O4S
Mol. Weight581.069 g/mol
IUPACN-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine
SMILESCS(=O)(=O)CCNCC1=CC=C(O1)C2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl
InChIInChI=1S/C29H26ClFN4O4S/c1-40(36,37)12-11-32-16-23-7-10-27(39-23)20-5-8-26-24(14-20)29(34-18-33-26)35-22-6-9-28(25(30)15-22)38-17-19-3-2-4-21(31)13-19/h2-10,13-15,18,32H,11-12,16-17H2,1H3,(H,33,34,35)
InChI KeyBCFGMOOMADDAQU-UHFFFAOYSA-N
Purity—
Description
Overview
Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer
Anant Labs manufacture and furnish high quality Lapatinib impurities for global markets. Our Lapatinib EP Impurities are used by API manufacturers and fully integrated pharmaceutical companies worldwide.
Synonyms
Lapatinib231277-92-2GW572016GW 572016GW-572016GSK 572016DTXSID7046675n-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-4-quinazolinamineGSK-5720160VUA21238F
